B8F.DE

Biofrontera AG [B8F.DE] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

B8F.DE Stock Summary

In the News

B8F.DE Financial details

Company Rating
-
Market Cap
21.69M
Income
-8.61M
Revenue
28.63M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
91
Optionable
No
Shortable
Yes
Earnings
22 Apr 2024
P/E
-3.65
Forward P/E
-
PEG
0.3
P/S
1.11
P/B
2.26
P/C
-
P/FCF
-
Quick Ratio
1.1
Current Ratio
1.72
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.14
EPS next Y
-
EPS next Q
-
EPS this Y
-216.67%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
32.3%
Revenue last 5Y
4.05%
Revenue Q/Q
-41.47%
EPS Q/Q
-1061.54%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-36%
ROE
-51%
ROC
0.07%
Gross Margin
80%
Oper. Margin
4%
Profit Margin
-30%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.3-1.3
52W High
-
52W Low
-
RSI
-
Rel Volume
5.07
Avg Volume
9.03K
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
0.657
-
-
Volatility
1.92%, 1.92%
Prev Close
-
Price
-
Change
-

Something similar

Top by Market Cap
BRK-A
AMZN
TSLA
BRH.DE
1YD.DE
Same Sector
ALSPW.PA
AIH
8037.HK
IONS
1358.HK
Check Those
WOR
WAVE.PA
0799.HK
1787.HK
002667.SZ
Similar Market Cap
VRCI.L
ITIM.L
APRT
EGPT
TEDU

Company Profile

Healthcare Drug Manufacturers - Specialty & Generic
  • Volume Average 9.03K
  • Market Capitalization 21.69M
  • Employee 91
  • CEO Ms. Pilar de la Huerta Martinez
  • Headquarters Leverkusen,DE
  • IPO Date 2006-10-31
  • Website https://www.biofrontera.com

Biofrontera AG, a biopharmaceutical company, engages in the research, development, and marketing of dermatological products. Its products include Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. The company also develops RhodoLED XL for the treatment of multiple interspersed lesions; Belixos, a modern active cosmetic product for irritated and sensitive skin; and Xepi for the treatment of antibiotic-resistant bacteria. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.